SG11201604979WA - Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists - Google Patents

Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

Info

Publication number
SG11201604979WA
SG11201604979WA SG11201604979WA SG11201604979WA SG11201604979WA SG 11201604979W A SG11201604979W A SG 11201604979WA SG 11201604979W A SG11201604979W A SG 11201604979WA SG 11201604979W A SG11201604979W A SG 11201604979WA SG 11201604979W A SG11201604979W A SG 11201604979WA
Authority
SG
Singapore
Prior art keywords
binding
combination therapy
agonists
antagonists
axis
Prior art date
Application number
SG11201604979WA
Inventor
Jeanne Cheung
Jeong Kim
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG11201604979WA publication Critical patent/SG11201604979WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SG11201604979WA 2013-12-17 2014-12-17 Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists SG11201604979WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361917264P 2013-12-17 2013-12-17
US201462080991P 2014-11-17 2014-11-17
PCT/US2014/070998 WO2015095423A2 (en) 2013-12-17 2014-12-17 Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

Publications (1)

Publication Number Publication Date
SG11201604979WA true SG11201604979WA (en) 2016-07-28

Family

ID=52293264

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201604979WA SG11201604979WA (en) 2013-12-17 2014-12-17 Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

Country Status (12)

Country Link
US (2) US20150190506A1 (en)
EP (2) EP3083687A2 (en)
JP (1) JP2017501167A (en)
KR (1) KR20160099092A (en)
CN (1) CN106102774A (en)
AU (1) AU2014364606A1 (en)
BR (1) BR112016013963A2 (en)
CA (1) CA2934028A1 (en)
IL (1) IL246251A0 (en)
MX (1) MX2016007965A (en)
SG (1) SG11201604979WA (en)
WO (1) WO2015095423A2 (en)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114835812A (en) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 anti-PD-L1 antibodies and their use for enhancing T cell function
WO2013181452A1 (en) 2012-05-31 2013-12-05 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
SG10201708048XA (en) 2013-03-18 2017-10-30 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
KR102363008B1 (en) 2014-02-10 2022-02-16 메르크 파텐트 게엠베하 TARGETED TGFβ INHIBITION
MX2016011993A (en) 2014-03-14 2016-12-09 Novartis Ag Antibody molecules to lag-3 and uses thereof.
US9822186B2 (en) 2014-03-28 2017-11-21 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
CA2943834A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
US11186640B2 (en) * 2014-07-31 2021-11-30 The University Of Western Australia Method for the identification of immunotherapy-drug combinations using a network approach
EP3925622A1 (en) 2014-09-13 2021-12-22 Novartis AG Combination therapies
CN107106687A (en) * 2014-10-03 2017-08-29 诺华股份有限公司 Combined therapy
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
AU2015343337A1 (en) 2014-11-03 2017-06-15 Genentech, Inc. Assays for detecting T cell immune subsets and methods of use thereof
SG11201703521UA (en) 2014-11-03 2017-05-30 Genentech Inc Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
MA55043A (en) 2014-11-26 2021-12-29 Xencor Inc HETERODIMERIC ANTIGEN-BINDING ANTIGEN CD3 AND CD20 ANTIGEN
MA41019A (en) 2014-11-26 2021-05-05 Xencor Inc HETERODIMERIC ANTIBODIES BINDING TO CD3 AND CD38 ANTIGENS
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
BR112017017884A2 (en) 2015-02-24 2018-04-10 Univ California binding triggered transcriptional switches and methods of using them
SG10201810615VA (en) 2015-02-26 2019-01-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
TWI820377B (en) 2015-05-07 2023-11-01 美商艾吉納斯公司 Anti-ox40 antibodies and methods of use thereof
BR112017024770A2 (en) * 2015-05-21 2018-07-31 Alligator Bioscience Ab innovative polypeptides
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
US20180237534A1 (en) 2015-05-29 2018-08-23 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
EP3303397A1 (en) * 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
IL256245B (en) 2015-06-16 2022-09-01 Merck Patent Gmbh Pd-l1 antagonist combination treatments
SG10201913303XA (en) 2015-07-13 2020-03-30 Cytomx Therapeutics Inc Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
KR20180036974A (en) 2015-07-16 2018-04-10 바이오엑셀 테라퓨틱스 인코포레이티드 A novel approach to the treatment of cancer using immunomodulation
WO2017024032A2 (en) 2015-08-03 2017-02-09 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation
BR112018002436A2 (en) * 2015-08-04 2018-09-18 Glaxosmithkline Ip Dev Ltd combination treatment of methods uses of these
US20180222989A1 (en) * 2015-08-04 2018-08-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
TW201716084A (en) * 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 Combinations and uses and treatments thereof
PE20181322A1 (en) 2015-09-01 2018-08-14 Agenus Inc ANTI-PD1 ANTIBODY AND ITS METHODS OF USE
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
US10894044B2 (en) 2015-09-16 2021-01-19 Board Of Regents, The University Of Texas System Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer
UA126549C2 (en) 2015-10-01 2022-11-02 Хіт Байолоджикс, Інк. Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
EP3356403A2 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
HUE055407T2 (en) 2015-10-02 2021-11-29 Hoffmann La Roche Bispecific antibodies specific for pd1 and tim3
KR20180084772A (en) * 2015-10-08 2018-07-25 마크로제닉스, 인크. Combination Therapy for Cancer Treatment
TWI805542B (en) * 2015-10-23 2023-06-21 日商坎巴斯有限公司 Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
WO2017093942A1 (en) * 2015-12-01 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
MA43389A (en) * 2015-12-02 2021-05-12 Agenus Inc ANTI-OX40 ANTIBODIES AND PROCESSES FOR USE
MA44312A (en) 2015-12-02 2018-10-10 Agenus Inc ANTIBODIES AND THEIR METHODS OF USE
CA3006963A1 (en) * 2015-12-03 2017-06-08 Ludwig Institute For Cancer Research Ltd. Anti-ox40 antibodies and methods of use thereof
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
US10596257B2 (en) 2016-01-08 2020-03-24 Hoffmann-La Roche Inc. Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
BR112018013677A2 (en) 2016-01-11 2019-01-22 Inhibrx Inc multivalent and multispecific 41bb binding fusion proteins
WO2017123673A2 (en) * 2016-01-11 2017-07-20 Inhibrx Lp Multivalent and multispecific ox40-binding fusion proteins
US20190031765A1 (en) 2016-01-25 2019-01-31 Pfizer Inc. Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer
AU2017225854B2 (en) 2016-02-29 2020-11-19 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
CA3015913A1 (en) 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
US10730950B2 (en) * 2016-03-08 2020-08-04 Janssen Biotech, Inc. GITR antibodies, methods, and uses
DE102016105069A1 (en) 2016-03-18 2017-09-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Antiviral immunotherapy by membrane receptor ligation
AU2017261354A1 (en) * 2016-05-06 2018-11-29 Exicure Operating Company Spherical Nucleic Acid TLR9 agonists
AR108377A1 (en) 2016-05-06 2018-08-15 Medimmune Llc BISPECIFIC UNION PROTEINS AND ITS USES
EP3243832A1 (en) * 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
CN109476718B (en) 2016-05-18 2023-07-04 莫得纳特斯公司 Combination of MRNA encoding immunomodulatory polypeptides and uses thereof
JP7246930B2 (en) 2016-05-18 2023-03-28 モデルナティエックス インコーポレイテッド Polynucleotides encoding interleukin-12 (IL12) and uses thereof
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
KR102523402B1 (en) 2016-06-14 2023-04-19 젠코어 인코포레이티드 Bispecific Checkpoint Inhibitor Antibodies
JP7021127B2 (en) 2016-06-28 2022-02-16 ゼンコア インコーポレイテッド Heterodimer antibody that binds to somatostatin receptor 2
JP7011764B2 (en) 2016-07-07 2022-01-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Antibody adjuvant complex
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
US20190175755A1 (en) * 2016-08-23 2019-06-13 The Johns Hopkins University Immunoswitch nanoparticles for reprogrammed t cell responses
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CA3038020A1 (en) 2016-09-23 2018-03-29 Merus N.V. Bispecific binding molecules that bind cd137
JP2019534251A (en) * 2016-09-29 2019-11-28 ジェネンテック， インコーポレイテッド Combination therapy using MEK inhibitor, PD-1 axis inhibitor, and taxane
CA3038712A1 (en) 2016-10-06 2018-04-12 Genentech, Inc. Therapeutic and diagnostic methods for cancer
JP2019530704A (en) 2016-10-06 2019-10-24 ファイザー・インコーポレイテッド Avelumab dosing regimen for the treatment of cancer
EA037973B1 (en) * 2016-10-12 2021-06-18 Янссен Байотек, Инк. Gitr antibodies, methods and uses
TWI788307B (en) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
MA47236A (en) 2017-01-06 2019-11-13 Iovance Biotherapeutics Inc TUMOR INFILTRATION LYMPHOCYTE (TIL) EXPANSION WITH TUMOR NECROSIS FACTOR (TNFRSF) SUPERFAMILY RECEPTOR AGONISTS AND THERAPEUTIC COMBINATIONS OF TIL AND TNFRSF AGONISTS
US11192933B2 (en) 2017-02-27 2021-12-07 Shattuck Labs, Inc. VSIG8-based chimeric proteins
MX2019009812A (en) 2017-02-27 2019-10-14 Shattuck Labs Inc Tigit- and light-based chimeric proteins.
MX2019010173A (en) 2017-02-27 2019-11-21 Shattuck Labs Inc Csf1r-based chimeric proteins.
CN108623686A (en) 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 Anti- OX40 antibody and application thereof
US11884738B2 (en) * 2017-03-31 2024-01-30 The University Of North Carolina At Chapel Hill Methods and compositions for activation of T cells using nanoparticles conjugated with multiple ligands for binding receptors on T cells
HUE059885T2 (en) 2017-04-03 2023-01-28 Hoffmann La Roche Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
TWI690538B (en) 2017-04-05 2020-04-11 瑞士商赫孚孟拉羅股份公司 Bispecific antibodies specifically binding to pd1 and lag3
CN110621787A (en) * 2017-04-14 2019-12-27 豪夫迈·罗氏有限公司 Methods for diagnosis and treatment of cancer
CN110582303A (en) 2017-04-20 2019-12-17 Adc治疗有限公司 Combination therapy with anti-CD 25 antibody-drug conjugates
JP7408396B2 (en) 2017-04-20 2024-01-05 アーデーセー セラピューティクス ソシエテ アノニム combination therapy
US11819517B2 (en) 2017-06-05 2023-11-21 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
BR112019026564A2 (en) 2017-06-14 2020-06-30 Adc Therapeutics Sa dosing regimens for administration of an anti-cd19 adc
JP2020527351A (en) 2017-07-21 2020-09-10 ジェネンテック， インコーポレイテッド Cancer treatment and diagnosis
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CA3082383A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
EP3710576A1 (en) 2017-11-17 2020-09-23 Iovance Biotherapeutics, Inc. Til expansion from fine needle aspirates and small biopsies
JP2021506291A (en) 2017-12-19 2021-02-22 ゼンコア インコーポレイテッド Modified IL-2 FC fusion protein
WO2019129137A1 (en) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 Anti-lag-3 antibody and uses thereof
CN109970856B (en) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 anti-LAG-3 antibodies and uses thereof
CN108218990B (en) * 2017-12-29 2021-03-02 南京优迈生物科技有限公司 Isolated antibodies or antigen binding fragments thereof and their use in tumor therapy
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
CN117866899A (en) 2018-01-08 2024-04-12 艾欧凡斯生物治疗公司 Method for producing a TIL product enriched in tumor antigen specific T cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
KR20200119246A (en) 2018-01-12 2020-10-19 이엔비 테라퓨틱스, 인크. Deuterated compounds, compositions, and methods for treating cancer associated with ETBR activation
CN111393529B (en) * 2018-01-29 2022-02-22 康源博创生物科技(北京)有限公司 anti-OX 40 antibodies that non-competitively bind to OX40L
WO2019157124A1 (en) * 2018-02-08 2019-08-15 Bristol-Myers Squibb Company Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
JP2021512962A (en) 2018-02-13 2021-05-20 アイオバンス バイオセラピューティクス，インコーポレイテッド Expansion culture of tumor-infiltrating lymphocytes (TIL) with adenosine A2A receptor antagonist and therapeutic combination of TIL and adenosine A2A receptor antagonist
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CN112437777A (en) 2018-04-18 2021-03-02 Xencor股份有限公司 TIM-3 targeting heterodimeric fusion proteins comprising an IL-15/IL-15RA Fc fusion protein and a TIM-3 antigen binding domain
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
CA3098303A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2021524449A (en) 2018-05-23 2021-09-13 アーデーセー セラピューティクス ソシエテ アノニム Molecular adjuvant
US11447556B2 (en) 2018-08-13 2022-09-20 Inhibex, Inc. OX40-binding polypeptides and uses thereof
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
TW202031273A (en) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 Treatment of nsclc patients refractory for anti-pd-1 antibody
KR20210064269A (en) 2018-09-20 2021-06-02 이오반스 바이오테라퓨틱스, 인크. Expansion of TILs from cryopreserved tumor samples
CN113195523A (en) 2018-10-03 2021-07-30 Xencor股份有限公司 IL-12 heterodimer Fc fusion proteins
WO2020096927A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
BR112021008549A2 (en) 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Method of treating non-small cell lung cancer with a population of tumor-infiltrating lymphocytes
CN113272420A (en) 2018-11-05 2021-08-17 艾欧凡斯生物治疗公司 Improved selection of tumor-reactive T cells
JOP20210094A1 (en) 2018-11-05 2023-01-30 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2020131547A1 (en) 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
CN114173875A (en) 2019-03-01 2022-03-11 Xencor股份有限公司 Heterodimeric antibodies that bind ENPP3 and CD3
KR20220004634A (en) 2019-03-15 2022-01-11 볼트 바이오테라퓨틱스 인코퍼레이티드 Immunoconjugates targeting HER2
MX2021011608A (en) 2019-03-29 2021-12-10 Myst Therapeutics Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods.
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
CA3141452A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
AU2020281535A1 (en) 2019-05-24 2022-01-27 Merck Patent Gmbh Combination therapies using CDK inhibitors
WO2021029368A1 (en) 2019-08-09 2021-02-18 国立研究開発法人理化学研究所 Combined use of artificial adjuvant vector cells and an immunostimulant
EP4048295A1 (en) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2023503396A (en) * 2019-11-21 2023-01-30 ベイジーン リミテッド Methods of treating cancer using anti-OX40 antibodies in combination with anti-PD1 antibodies or anti-PDL1 antibodies
JP2023504042A (en) 2019-11-27 2023-02-01 ミスト セラピューティクス リミテッド ライアビリティ カンパニー Methods of generating tumor-reactive T-cell compositions using modulators
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
WO2021118990A1 (en) 2019-12-11 2021-06-17 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
BR112022016490A2 (en) 2020-02-27 2022-10-11 Myst Therapeutics Llc METHODS FOR EX VIVO ENRICHMENT AND EXPANSION OF TUMOR T-REACTIVE CELLS AND RELATED COMPOSITIONS THEREOF
JP2023523855A (en) 2020-05-04 2023-06-07 アイオバンス バイオセラピューティクス，インコーポレイテッド Method for producing tumor-infiltrating lymphocytes and their use in immunotherapy
JP2023524108A (en) 2020-05-04 2023-06-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Selection of improved tumor-reactive T cells
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc Anti-cd28 compositions
JP2023546359A (en) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド Treatment of NSCLC patients with tumor-infiltrating lymphocyte therapy
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022087361A1 (en) * 2020-10-22 2022-04-28 The Regents Of The University Of California Monoamine oxidase blockade therapy for treating cancer through regulating antitumor t cell immunity
WO2022100659A1 (en) * 2020-11-12 2022-05-19 Curon Biopharmaceutical (Shanghai) Co., Limited Combination therapy and methods utilizing the same
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
JP2024501452A (en) 2020-12-11 2024-01-12 アイオバンス バイオセラピューティクス，インコーポレイテッド Treatment of cancer patients with tumor-infiltrating lymphocyte therapy in combination with BRAF inhibitors and/or MEK inhibitors
WO2022130206A1 (en) 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
EP4262827A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
JP2024500847A (en) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド Chimeric antigen receptor systems with compatible receptor specificities
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
KR20240037185A (en) 2021-04-19 2024-03-21 이오반스 바이오테라퓨틱스, 인크. Chimeric costimulatory receptors, chemokine receptors, and their uses in cellular immunotherapy
TW202327631A (en) 2021-07-28 2023-07-16 美商艾歐凡斯生物治療公司 Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
AR127482A1 (en) 2021-10-27 2024-01-31 Iovance Biotherapeutics Inc SYSTEMS AND METHODS TO COORDINATE THE MANUFACTURE OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY
WO2023086803A1 (en) 2021-11-10 2023-05-19 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies

Family Cites Families (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH119431A (en) 1926-04-21 1927-03-16 Beck Sigmund Painter's brush.
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
CU22545A1 (en) 1994-11-18 1999-03-31 Centro Inmunologia Molecular OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2052027T5 (en) 1988-11-11 2005-04-16 Medical Research Council IMMUNOGLOBULINE VARIABLE DOMAIN SEQUENCE CLONING.
FR2646437B1 (en) 1989-04-28 1991-08-30 Transgene Sa NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
ES2096590T3 (en) 1989-06-29 1997-03-16 Medarex Inc BI-SPECIFIC REAGENTS FOR AIDS THERAPY.
DE69025946T2 (en) 1989-09-08 1996-10-17 Univ Johns Hopkins MODIFICATIONS OF THE STRUCTURE OF THE EGF RECEPTOR GENE IN HUMAN GLIOMA
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
EP0547065B1 (en) 1990-06-29 2001-08-29 Large Scale Biology Corporation Melanin production by transformed microorganisms
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2108048T3 (en) 1990-08-29 1997-12-16 Genpharm Int PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
JP3951062B2 (en) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド Expression of antibody fragments with cysteine present at least as a free thiol in E. coli for the production of bifunctional F (ab ') 2 antibodies
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
CA2146559A1 (en) 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
RO118524B1 (en) 1992-11-13 2003-06-30 Idec Pharmaceuticals Corp San Method for treating a disorder related to cells b
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69428764T2 (en) 1993-12-24 2002-06-20 Merck Patent Gmbh immunoconjugates
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
EP0772609B1 (en) 1994-07-21 1999-02-24 Akzo Nobel N.V. Cyclic ketone peroxide formulations
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
CA2216796C (en) 1995-03-30 2003-09-02 Pfizer Inc. Quinazoline derivatives
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
KR100437582B1 (en) 1995-07-06 2004-12-17 노파르티스 아게 Pyrrolopyrimidines and Processes for the Preparation Thereof
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
CA2249446C (en) 1996-04-12 2008-06-17 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
WO1998002434A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ATE254502T1 (en) 1996-08-30 2003-12-15 Upfront Chromatography As ISOLATION OF IMMUNOGLOBULINS
ID18494A (en) 1996-10-02 1998-04-16 Novartis Ag PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US20080318254A9 (en) 1997-03-10 2008-12-25 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (en) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Substituted 3-cyan chinolines
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998050038A1 (en) 1997-05-06 1998-11-12 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (en) 1997-06-24 2005-12-01 Genentech, Inc. PROCEDURE AND COMPOSITIONS OF GALACTOSILATED GLICOPROTEINS.
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
WO1999024037A1 (en) 1997-11-06 1999-05-20 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
DK2180007T4 (en) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity
PT1131304E (en) 1998-11-19 2003-04-30 Warner Lambert Co N-4- (3-CHLORO-4-FLUORO-PHENYLAMINO) -7- (3-MORFOLIN-4-IL-PROPOXY) -QUINAZOLIN-6-IL | -ACRYLAMIDE AN IRREVERSIVAL INJECTOR OF TYROSOS KINASES
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (en) 1999-01-15 2010-02-02 제넨테크, 인크. Polypeptide Variants with Altered Effector Function
ATE402267T1 (en) 1999-03-30 2008-08-15 Japan Tobacco Inc METHOD FOR PRODUCING MONOCLONAL ANTIBODIES
DK2270147T4 (en) 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd METHOD OF MONITORING THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2385347C (en) 1999-10-04 2009-12-15 Medicago Inc. Method for regulating transcription of foreign genes
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2424602C (en) 2000-10-06 2012-09-18 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-producing cell
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1487996B (en) 2000-11-30 2010-06-16 米德列斯公司 Transgenic transchromosomal rodents for making human antibodies
WO2002092017A2 (en) 2001-05-16 2002-11-21 Albert Einstein College Of Medicine Of Yeshiva University Human antipneumococcal antibodies from non-human animals
KR20040054669A (en) 2001-08-03 2004-06-25 글리카트 바이오테크놀로지 아게 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
PT1425389E (en) 2001-08-23 2012-02-07 Genmab As Human antibodies specific for interleukin 15 (il-15)
CN100423777C (en) 2001-10-25 2008-10-08 杰南技术公司 Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
WO2003085118A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
CA2481657A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
EP1525223B1 (en) 2002-06-13 2007-11-21 Crucell Holland B.V. Ox40 (=cd134) receptor agonists and therapeutic use
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP4351674B2 (en) 2002-12-16 2009-10-28 ジェネンテック・インコーポレーテッド Immunoglobulin variants and their use and use
EP1585767A2 (en) 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries
CN1761482A (en) 2003-01-17 2006-04-19 纽约州立大学研究基金会 The antigen relevant with cancer of pancreas, at its antibody and diagnosis and Therapeutic Method
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CA2526398C (en) 2003-05-21 2014-07-15 Medarex, Inc. Human monoclonal antibodies against bacillus anthracis protective antigen
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
WO2005035778A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY USING RNA INHIBITING THE FUNCTION OF α1,6-FUCOSYLTRANSFERASE
RS57466B1 (en) 2003-11-05 2018-09-28 Roche Glycart Ag Antigen binding molecules with increased fc receptor binding affinity and effector function
JPWO2005053742A1 (en) 2003-12-04 2007-06-28 協和醗酵工業株式会社 Medicament containing antibody composition
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
BR122019012028B1 (en) 2004-04-13 2023-09-26 F. Hoffmann-La Roche Ag ANTI-P-SELECTIN ANTIBODIES, NUCLEIC ACID MOLECULE, VECTOR, AND COMPOSITION
TWI380996B (en) 2004-09-17 2013-01-01 Hoffmann La Roche Anti-ox40l antibodies
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
EP1814568A4 (en) 2004-10-29 2009-08-12 Univ Southern California Combination cancer immunotherapy with co-stimulatory molecules
CA2606809C (en) 2005-05-06 2016-01-05 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
PL2439273T3 (en) 2005-05-09 2019-08-30 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
RS54271B1 (en) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
ES2577292T3 (en) 2005-11-07 2016-07-14 Genentech, Inc. Binding polypeptides with diversified VH / VL hypervariable sequences and consensus
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 Liquid crystal panel drive device and its drive method
SI2594590T1 (en) 2007-12-14 2015-03-31 Bristol-Myers Squibb Company Method of producing binding molecules for the human OX40 receptor
HUE034465T2 (en) 2008-02-11 2018-02-28 Cure Tech Ltd Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
MX2011002252A (en) * 2008-08-25 2011-06-24 Amplimmune Inc Compositions of pd-1 antagonists and methods of use.
KR20110074850A (en) 2008-08-25 2011-07-04 앰플리뮨, 인크. Pd-1 antagonists and methods of use thereof
CN114835812A (en) * 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 anti-PD-L1 antibodies and their use for enhancing T cell function
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
LT3279215T (en) 2009-11-24 2020-04-10 Medimmune Limited Targeted binding agents against b7-h1
PE20131403A1 (en) 2010-08-23 2014-01-10 Univ Texas ANTI-OX40 ANTIBODIES AND METHODS OF USING THEM
AU2012290121B2 (en) * 2011-08-01 2015-11-26 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
KR101685262B1 (en) 2011-08-23 2016-12-21 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Anti-ox40 antibodies and methods of using the same
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
SG10201708048XA (en) 2013-03-18 2017-10-30 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
TW201619200A (en) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 Humanized anti-OX40 antibodies and uses thereof
EP4245376A3 (en) * 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2017025610A1 (en) * 2015-08-12 2017-02-16 Medimmune Limited Gitrl fusion proteins and uses thereof

Also Published As

Publication number Publication date
JP2017501167A (en) 2017-01-12
WO2015095423A3 (en) 2015-08-13
EP3527587A1 (en) 2019-08-21
CN106102774A (en) 2016-11-09
BR112016013963A2 (en) 2017-10-10
WO2015095423A2 (en) 2015-06-25
AU2014364606A1 (en) 2016-07-07
IL246251A0 (en) 2016-07-31
US20150190506A1 (en) 2015-07-09
MX2016007965A (en) 2016-10-28
EP3083687A2 (en) 2016-10-26
US20180303936A1 (en) 2018-10-25
KR20160099092A (en) 2016-08-19
CA2934028A1 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
IL246251A0 (en) Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
IL252251A0 (en) Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
IL272617A (en) Conjugated antisense compounds and their use
IL251618A0 (en) Combination therapy comprising ox40 binding agonists and tigit inhibitors
IL248004A0 (en) Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
HK1223975A1 (en) Nanobubble-containing composition and use thereof
IL246221A0 (en) Indazoles and use thereof
GB201320729D0 (en) Therapeutic compounds and their use
IL286759A (en) Therapeutic methods and compositions
GB201317286D0 (en) Composition and Use
HK1216890A1 (en) Benzyl substituted pyrazolopyridines and use thereof
HRP20181536T1 (en) Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists
SI3081256T1 (en) Electrotherapy device
EP2954908A4 (en) Coating composition and medical device
GB201310921D0 (en) Peptide-resin conjugate and use thereof
GB201311361D0 (en) Compounds and their therapeutic use
GB201307989D0 (en) Novel combinations and use
GB201301979D0 (en) New composition and use thereof
EP2983474A4 (en) Herbicide composition comprising clomazone and use
EP2946016A4 (en) Adenoviruses and their use
GB201318151D0 (en) Composition and device
GB201308736D0 (en) Compounds and their therapeutic use
GB201322467D0 (en) Composition and use
GB201317804D0 (en) Therapeutic compounds and their use
GB201316173D0 (en) Compounds and their therapeutic use